JP2014505690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505690A5 JP2014505690A5 JP2013549487A JP2013549487A JP2014505690A5 JP 2014505690 A5 JP2014505690 A5 JP 2014505690A5 JP 2013549487 A JP2013549487 A JP 2013549487A JP 2013549487 A JP2013549487 A JP 2013549487A JP 2014505690 A5 JP2014505690 A5 JP 2014505690A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorder
- hydrogen
- disease
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 201000000980 schizophrenia Diseases 0.000 claims 10
- 208000028017 Psychotic disease Diseases 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 208000028698 Cognitive impairment Diseases 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000030988 Schizoid Personality disease Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- -1 methyl compound Chemical class 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000024817 paranoid personality disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 208000024335 physical disease Diseases 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- BHYRFKDBQRBVEU-UHFFFAOYSA-N Cc1cnc(C)c2nc(CCc3nc(c4c(cc5)nccc4)c5[n]3C)n[n]12 Chemical compound Cc1cnc(C)c2nc(CCc3nc(c4c(cc5)nccc4)c5[n]3C)n[n]12 BHYRFKDBQRBVEU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431769P | 2011-01-11 | 2011-01-11 | |
| US61/431,769 | 2011-01-11 | ||
| PCT/US2012/020734 WO2012096929A2 (en) | 2011-01-11 | 2012-01-10 | Heteroaryl compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016028453A Division JP6261631B2 (ja) | 2011-01-11 | 2016-02-18 | ヘテロアリール化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505690A JP2014505690A (ja) | 2014-03-06 |
| JP2014505690A5 true JP2014505690A5 (enExample) | 2015-03-12 |
| JP6106603B2 JP6106603B2 (ja) | 2017-04-05 |
Family
ID=46455746
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549487A Expired - Fee Related JP6106603B2 (ja) | 2011-01-11 | 2012-01-10 | ヘテロアリール化合物及びその使用方法 |
| JP2016028453A Expired - Fee Related JP6261631B2 (ja) | 2011-01-11 | 2016-02-18 | ヘテロアリール化合物及びその使用方法 |
| JP2017237313A Pending JP2018058890A (ja) | 2011-01-11 | 2017-12-12 | ヘテロアリール化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016028453A Expired - Fee Related JP6261631B2 (ja) | 2011-01-11 | 2016-02-18 | ヘテロアリール化合物及びその使用方法 |
| JP2017237313A Pending JP2018058890A (ja) | 2011-01-11 | 2017-12-12 | ヘテロアリール化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8765760B2 (enExample) |
| EP (2) | EP3210984B1 (enExample) |
| JP (3) | JP6106603B2 (enExample) |
| CN (2) | CN107141309A (enExample) |
| AU (2) | AU2012205687B2 (enExample) |
| CA (1) | CA2824047C (enExample) |
| ES (1) | ES2627788T3 (enExample) |
| WO (1) | WO2012096929A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2824047C (en) * | 2011-01-11 | 2019-06-18 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| JP6236439B2 (ja) | 2012-06-19 | 2017-11-22 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ヘテロアリール化合物及びその使用方法 |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| EP2890370B1 (en) * | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
| US9163027B2 (en) | 2012-11-21 | 2015-10-20 | Stategics, Inc. | Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival |
| WO2014085284A1 (en) | 2012-11-29 | 2014-06-05 | Sunovion Pharmaceuticals Inc. | Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system |
| EA201591610A1 (ru) * | 2013-03-14 | 2015-12-30 | Курадев Фарма Прайвит Лтд. | Ингибиторы кинуренинового пути |
| KR20160089474A (ko) * | 2013-11-28 | 2016-07-27 | 에프. 호프만-라 로슈 아게 | 이미다졸 유도체 |
| CN108623619B (zh) * | 2017-03-17 | 2021-11-05 | 江苏豪森药业集团有限公司 | 制备C-Met酪氨酸激酶抑制剂的方法 |
| CN108926528A (zh) * | 2017-05-25 | 2018-12-04 | 北京万全德众医药生物技术有限公司 | 含有氨磺必利树脂酸盐的口服液体组合物 |
| WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CN108440284A (zh) * | 2018-03-26 | 2018-08-24 | 新沂市中诺新材料科技有限公司 | 一种有机合成中间体丙酮酸乙酯的合成方法 |
| CN111902993A (zh) | 2018-03-26 | 2020-11-06 | 京瓷株式会社 | 控制装置、信息处理装置及蓄电池检索系统 |
| CN109350617A (zh) * | 2018-04-22 | 2019-02-19 | 孙凤兰 | 化合物在制备治疗糖尿病的药物中的用途 |
| US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
| JOP20200342A1 (ar) | 2018-07-05 | 2020-12-30 | Incyte Corp | مشتقات بيرازين مدمجة كمثبطات a2a/a2b |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US11423743B2 (en) | 2019-10-13 | 2022-08-23 | Everi Games, Inc. | Method, apparatus, and program product for triggering and controlling gaming machine operation in reel-type games |
| CN112138007B (zh) * | 2020-09-23 | 2021-12-28 | 广州中医药大学(广州中医药研究院) | 氧化小檗碱在制备代谢性疾病药物中的应用及包含氧化小檗碱的药物组合物 |
| MX2023004102A (es) * | 2020-10-09 | 2023-04-27 | Shujing Biopharma Co Ltd | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. |
| CN113797200B (zh) * | 2021-10-21 | 2022-11-04 | 中国人民解放军海军军医大学 | 小分子化合物匹莫范色林在制备抗SARS-CoV-2药物中的应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1115255B (de) * | 1959-12-02 | 1961-10-19 | Bayer Ag | Verfahren zur Herstellung von Bis-benzoxazolen |
| US3250780A (en) * | 1962-05-21 | 1966-05-10 | Union Oil Co | Bis-benzoxazolythyl sulfide |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| NL7204972A (enExample) * | 1971-04-21 | 1972-10-24 | ||
| US3897432A (en) | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5439093B2 (enExample) | 1974-08-24 | 1979-11-26 | ||
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5439093A (en) * | 1977-08-30 | 1979-03-24 | Kyorin Seiyaku Kk | Sstriazolo*1*55a*pyridine derivative |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| SE8600658D0 (sv) * | 1986-02-14 | 1986-02-14 | Haessle Ab | Novel composition of matter |
| DE3809868A1 (de) * | 1988-03-24 | 1989-10-05 | Boehringer Mannheim Gmbh | Neue heterocyclisch substituierte 5,7-dihydro-pyrrolo(3,2-f)benzoxazol-6-one, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6255091B1 (en) | 1995-04-28 | 2001-07-03 | Axys Pharmaceuticals, Inc. | Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions |
| US20040006011A1 (en) | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| ATE371659T1 (de) * | 1998-10-16 | 2007-09-15 | Merck Sharp & Dohme | Pyrazolotriazinderivate als gaba-rezeptorliganden |
| US20030191320A1 (en) * | 2000-10-18 | 2003-10-09 | Eliu Victor Paul | Process for the preparation of bis-benzazolyl compounds |
| JP2008530017A (ja) * | 2005-02-04 | 2008-08-07 | セノミックス インコーポレイテッド | 食料用組成物のための風味調整剤として連結された有機部分を含む分子 |
| JP5390186B2 (ja) * | 2005-08-12 | 2014-01-15 | ユナイテッド ステイツ ガバメント アズ レプリゼンティッド バイ ザ セクレタリー オブ ザ ユナイテッド ステイツ アーミー アンド ザ ユーエス アーミー メディカル リサーチ アンド マティリ | 広い抗菌スペクトルを有する抗菌性化合物 |
| EP1991540A1 (en) * | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| DE102006047618B3 (de) * | 2006-10-09 | 2007-11-15 | Clariant International Limited | Verfahren zur Herstellung von Bisbenzoxazolen |
| KR20090071612A (ko) | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
| WO2009039248A2 (en) * | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
| WO2009070583A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| US8133897B2 (en) * | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US20110224204A1 (en) | 2008-06-25 | 2011-09-15 | Richard Chesworth | Di-substituted phenyl compounds |
| CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| US8481532B2 (en) | 2008-07-09 | 2013-07-09 | Envivo Pharmaceuticals, Inc. | PDE-10 inhibitors |
| ES2654617T3 (es) | 2008-08-05 | 2018-02-14 | Omeros Corporation | Inhibidores de PDE10 y composiciones y procedimientos relacionados |
| JP5370884B2 (ja) * | 2008-08-29 | 2013-12-18 | Ｊｎｃ株式会社 | 液晶配向剤、液晶配向膜及び液晶表示素子 |
| JP5290406B2 (ja) | 2008-09-04 | 2013-09-18 | 田辺三菱製薬株式会社 | 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用 |
| JP2012506873A (ja) | 2008-10-28 | 2012-03-22 | シェーリング コーポレイション | 置換ピラゾロキノリンおよびそれらの誘導体 |
| US20100120763A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| US20100120762A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Triazine derivatives as inhibitors of phosphodiesterases |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| AR074343A1 (es) | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
| EP2389358B1 (en) | 2009-01-23 | 2015-09-16 | Acea Biosciences, Inc. | Synthetic process for anticancer drug fluorapacin and trisulfide derivatives |
| DE102009007038A1 (de) * | 2009-02-02 | 2010-08-05 | Merck Patent Gmbh | Metallkomplexe |
| WO2011047129A1 (en) * | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| EP3318561B1 (en) | 2010-05-26 | 2021-12-22 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2012044877A1 (en) * | 2010-10-01 | 2012-04-05 | Thomson Licensing | System and method for navigation in a user interfface |
| US8552045B2 (en) * | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| JO3089B1 (ar) * | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| CA2824047C (en) * | 2011-01-11 | 2019-06-18 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
-
2012
- 2012-01-10 CA CA2824047A patent/CA2824047C/en active Active
- 2012-01-10 US US13/347,541 patent/US8765760B2/en active Active
- 2012-01-10 EP EP17160357.4A patent/EP3210984B1/en active Active
- 2012-01-10 ES ES12734302.8T patent/ES2627788T3/es active Active
- 2012-01-10 AU AU2012205687A patent/AU2012205687B2/en not_active Ceased
- 2012-01-10 CN CN201710186503.6A patent/CN107141309A/zh active Pending
- 2012-01-10 EP EP12734302.8A patent/EP2663565B1/en not_active Not-in-force
- 2012-01-10 CN CN201280011263.1A patent/CN103619841B/zh not_active Expired - Fee Related
- 2012-01-10 JP JP2013549487A patent/JP6106603B2/ja not_active Expired - Fee Related
- 2012-01-10 WO PCT/US2012/020734 patent/WO2012096929A2/en not_active Ceased
-
2014
- 2014-06-06 US US14/298,691 patent/US9249162B2/en active Active
-
2015
- 2015-10-15 US US14/884,397 patent/US9856274B2/en active Active
-
2016
- 2016-02-18 JP JP2016028453A patent/JP6261631B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-14 AU AU2017204007A patent/AU2017204007B2/en not_active Ceased
- 2017-11-20 US US15/818,044 patent/US10570156B2/en active Active
- 2017-12-12 JP JP2017237313A patent/JP2018058890A/ja active Pending